Previous Close | 4.9000 |
Open | 4.8600 |
Bid | 0.0000 x 3200 |
Ask | 0.0000 x 4000 |
Day's Range | 4.7350 - 5.0200 |
52 Week Range | 4.7340 - 41.0000 |
Volume | |
Avg. Volume | 2,565,688 |
Market Cap | 720.731M |
Beta (5Y Monthly) | 2.24 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.4580 |
Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.63 |
Subscribe to Yahoo Finance Plus to view Fair Value for TGTX
Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ETNEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference taking place next week. A webcast of the presentation will be available for on demand download beginning on Tuesday, May 24, 2022, at 7:00 AM ET through Thursday M
If you want to know who really controls TG Therapeutics, Inc. ( NASDAQ:TGTX ), then you'll have to look at the makeup...
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?